Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer.
Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer.
复制标题
DOI：
10.1186/bcr1611
复制
发表时间：
2006
影响因子：
7.4
通讯作者：
Solomayer, Erich-Franz
中科院分区：
文献类型：
--
作者：
Fehm, Tanja;Becker, Sven;Becker-Pergola, Graziella;Sotlar, Karl;Gebauer, Gerhard;Duerr-Stoerzer, Silke;Neubauer, Hans;Wallwiener, Diethelm;Solomayer, Erich-Franz
新辅助全身治疗（NST）是一种既定的策略，以减少乳腺癌患者的肿瘤大小之前，保乳治疗。NST对这些患者肿瘤细胞播散的影响尚不清楚。本研究的目的是调查乳腺癌患者NST后播散性肿瘤细胞（DTC）的发生率，包括凋亡DTC，并调查DTC状态与治疗反应的相关性。157例NST后进行骨髓穿刺。用A45-B/B3抗细胞角蛋白抗体免疫细胞化学法检测DTC。为了检测凋亡DTC，使用抗体M30（Roche Diagnostics，德国），其检测仅在早期凋亡期间细胞角蛋白18的半胱天冬酶切割后表达的新表位。乳腺癌患者完成NST后DTC的发生率为53%。原发肿瘤无变化/进展的患者（69%）较原发肿瘤部分缓解或完全缓解的患者（46%）更容易观察到肿瘤扩散（P < 0.05）。然而，24例完全缓解的患者中有10例仍为骨髓阳性。157例乳腺癌患者中有36例（23%）存在凋亡性DTC。在部分缓解或完全缓解的患者中仅检测到14%的凋亡细胞，但在稳定疾病的患者中仅检测到5%。在肿瘤进展的患者中均未检测到凋亡DTC。乳腺癌患者的病理治疗反应反映在凋亡DTC的存在。然而，完全缓解的患者仍可能有非凋亡性DTC。这些患者也可能受益于二次辅助治疗。
Neoadjuvant systemic therapy (NST) is an established strategy to reduce tumor size in breast cancer patients prior to breast-conserving therapy. The effect of NST on tumor cell dissemination in these patients is not known. The aim of this study was to investigate the incidence of disseminated tumor cells (DTC), including apoptotic DTC, in breast cancer patients after NST, and to investigate the correlation of DTC status with therapy response. Bone marrow aspiration was performed in 157 patients after NST. DTC were detected by immunocytochemistry using the A45–B/B3 anticytokeratin antibody. To detect apoptotic DTC the antibody M30 (Roche Diagnostics, Germany) was used, which detects a neo-epitope expressed only after caspase cleavage of cytokeratin 18 during early apoptosis. The incidence of DTC in breast cancer patients was 53% after completion of NST. Tumor dissemination was observed more frequently in patients with no change/progressive disease (69%) than in patients with partial remission or complete remission of the primary tumor (46%) (P < 0.05). Ten out of 24 patients with complete remission, however, were still bone marrow positive. Apoptotic DTC were present in 36 of 157 (23%) breast cancer patients. Apoptotic cells only were detected in 14% of the patients with partial remission or complete remission, but were detected in just 5% of the patients with stable disease. Apoptotic DTC were detectable in none of the patients with tumor progression. The pathological therapy response in breast cancer patients is reflected by the presence of apoptotic DTC. Patients with complete remission, however, may still have nonapoptotic DTC. These patients may also benefit from secondary adjuvant therapy.
登录
查看更多内容
影响因子：
45.3
作者：
Kaufmann, M;von Minckwitz, G;Senn, HJ
通讯作者：
Senn, HJ
影响因子：
4.5
作者：
Borgen, E;Naume, B;Pantel, K
通讯作者：
Pantel, K
影响因子：
9.2
作者：
Rytömaa, M;Martins, LM;Downward, J
通讯作者：
Downward, J
影响因子：
4.5
作者：
Fehm, T;Solomayer, EF;Gebauer, G
通讯作者：
Gebauer, G
DOI：
10.1083/jcb.124.4.619
发表时间：
1994-02
期刊：
The Journal of cell biology
影响因子：
--
作者：
Frisch SM;Francis H
通讯作者：
Francis H